Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian Orthopedic ... market in Asia with analysis and forecast of revenue. The ... to grow to around $416.5 million by 2018, at a ... through the TOC of the Asian Orthopedic braces and support ... provided. This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... October 18, 2014 The report ... Trends and Forecasts to 2019", analyzes the global ... order to understand the industry details such as ... across various geographic regions. , Browse 81 Market ... Slides and in-depth TOC on “1,6-Hexanediol Market by ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5
... BEDFORD, Mass. and MADISON, Wis., July 17 ,Hologic, Inc. ... (Nasdaq:,TWTI) ("Third Wave"), today jointly announced the expiration of ... wholly-owned subsidiary Thunder,Tech Corp. (the "Purchaser") for all outstanding ... period expired, as scheduled, at 12:00,midnight, New York City ...
... Will Focus on Strategies to Promote Legislative Pathway for ... ... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals for unmet,medical needs, ... Ways and Means Committee from 2001 to 2007, has been,retained by ...
... Ablative Solution to Treat Deep Wrinkles and Significant Photo Damage,- ... Newest Addition Broadens Affirm(TM) Family to Provide Industry,s Most ... Comprehensive Anti-Aging Solution, ... ), a leading developer and manufacturer of a broad array ...
Cached Biology Technology:Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 2Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 3Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 4Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 5Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 2Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 3Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 4Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 2Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 3Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 4
(Date:10/16/2014)... and Washington land managers have a new synthesis of ... moist mixed-conifer (MMC) forests in the two states. ... in Eastern Oregon and Washington: A Synthesis of the ... a general technical report published by the U.S. Forest ... to a request from managers for a synthesis of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... In new research from Saint Louis University, investigators have ... responsible for the series of cellular events that lead to ... found that the brain toxin DOPAL plays a key role ... In earlier research, Saint Louis University investigators found ...
... about how the flea jumps, think again. In 1967, ... to catapult themselves into the air in an elastic ... debate raged about exactly how fleas harness this explosive ... hypotheses, but neither had access to the high speed ...
... 9, 2011 Qqest and M2SYS Technology, a global ... that allows Qqest to offer TimeForce time and attendance ... identification technology at their PC. M2SYS, RightPunch(TM) ... to seamlessly interface with Qqest,s TimeForce time and ...
Cached Biology News:SLU research implicates natural toxin as triggering Parkinson's disease 244-year-old mystery of how fleas jump resolved 244-year-old mystery of how fleas jump resolved 3Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3
... 140kDa GenBank Accession ... amino acids 926-941 (DKKVKPPFIPTIRGRE) of human PRK2. ... Quality Assurance Routinely evaluated by ... Stability 1 year at ...
Replacement Parts for Electrophoresis Apparatus...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
EMBP (FL-222)...
Biology Products: